Synergistic chemosensitization and inhibition of progression to androgen independence by antisense BCL-2 oligodeoxynucleotide and paclitaxel in the LNCAP prostate tumor model

International Journal of Cancer

Volumn 91, Issue 6, 2001, Pages 846-850

  Leung, Simon ^a   Miyake, Hideaki ^a   Zellweger, Tobias ^a   Tolcher, Anthony ^a   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgen independent; Antisense Bcl 2 oligodeoxynucleotide; Apoptosis; Paclitaxel; Prostate cancer

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CASTRATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; DNA PRIMERS; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0035869667     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1131>3.0.CO;2-Y     Document Type: Article

References (27)

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
2. A critical assessment of the role of chemotherapy for endocrine-resistant prostate carcinoma
3. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
4. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
5. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
6. Phase II trial of oral estramustine, oral etopside, and intravenous paclitaxel in hormone-refractory prostate cancer
7. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblast
8. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma
9. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
10. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
11. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line
12. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligonucleotides after castration in the LNCaP prostate tumor model
13. Complement activation and hemodynamic changes following intravenous administration of phosporothioate oligonucleotides in the monkey
14. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
15. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
16. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer
17. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
18. Targeting Bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense Bcl-2 oligodeoxynucleotides
19. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
20. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
21. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
22. Androgen induced resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells
23. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice
24. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells
25. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL
26. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
27. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors